Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Monte Rosa Therapeutics (GLUE – Research Report) today and set a price target of $21.00. The company’s shares closed yesterday at $5.85.
According to TipRanks, Tenthoff is a 5-star analyst with an average return of 17.1% and a 45.60% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Moderna, Crispr Therapeutics AG, and Xencor.
Currently, the analyst consensus on Monte Rosa Therapeutics is a Moderate Buy with an average price target of $22.20.
See the top stocks recommended by analysts >>
GLUE market cap is currently $288.8M and has a P/E ratio of -2.41.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.
Read More on GLUE:
- Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
- Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023
- Monte Rosa Therapeutics presents preclinical data from GSPT1 degrader program
- Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors
- Monte Rosa Therapeutics appoints Jan Skvarka to board of directors
